130 completed, 123 unknown, 119 recruiting, 58 not yet recruiting. 260 Phase 2, 155 Phase 1, 53 Not applicable, 51 Phase 3, 11 Phase 4.
Follow NSCLC: new trials by email Literature Review of NSCLC trials Research Report on NSCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2026-12-01 | 2026-08-04 |
| Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer TUB-040 - NSCLC, Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Gilead Sciences | 80 | 2026-11-01 | 2026-09-16 |
| A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) - NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 152 | 2026-11-01 | 2026-10-22 |
| SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET [225Ac]Ac-FL-261 - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Recruiting | Full-Life Technologies UK Limited | 208 | 2026-10-01 | 2026-10-16 |
| A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation Sosimerasib in combination with IN10018, Tislelizumab + Carboplatin + Pemetrexed - NSCLC | Phase 3 | Not yet recruiting | Shanghai Jeyou Pharmaceutical Co., Ltd. | 416 | 2026-10-01 | 2026-09-24 |
| Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer NovoTTF-200T System - NSCLC, Non Small Cell Lung Cancer | Not applicable | Withdrawn | University of Texas Southwestern Medical Center | 2026-10-01 | 2026-10-23 | |
| Neoadjuvant Iruplinalkib and Bevacizumab in ALK-positive NSCLC: A Phase II Single-arm Trial Bevacizumab combined with iruplinalkib as neoadjuvant therapy in ALK-positive NSCLC: - ALK, NSCLC | Not applicable | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 40 | 2026-09-15 | 2026-10-13 |
| Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial Cemiplimab - Nsclc, NSCLC Stage II | Phase 2 | Not yet recruiting | University of Maryland, Baltimore | 30 | 2026-09-01 | 2026-08-07 |
| SI-B036-ST-101 in Advanced/Metastatic Solid Tumors SI-B036 - Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors | Phase 1 | Not yet recruiting | SystImmune Inc. | 424 | 2026-09-01 | 2026-10-05 |
| Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC Gemcitabine + Ivonescimab - NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Swiss Cancer Institute | 47 | 2026-08-21 | 2026-08-26 |
| A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC Adebrelimab, Trastuzumab rezetecan - NSCLC | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 37 | 2026-08-20 | 2026-08-21 |
| Study of NXP900 With Lorlatinib in ALK+ Lung Cancer NXP900, Lorlatinib - ALK Positive, ALK Positive Non-small Cell Lung Cancer | Phase 1 | Recruiting | Nuvectis Pharma, Inc. | 54 | 2026-08-17 | 2026-08-25 |
| Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC zoldonrasib, Placebo, pembrolizumab - NSCLC, Non-small Cell Lung Cancer | Phase 3 | Recruiting | Revolution Medicines, Inc. | 430 | 2026-08-14 | 2026-08-20 |
| SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer SKB264+SKB118 - NSCLC | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 206 | 2026-08-07 | 2026-08-12 |
| The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or Metastatic NSCLC With HER2 Over Expression Experimental Group - NSCLC | Phase 2 | Not yet recruiting | Hunan Province Tumor Hospital | 30 | 2026-07-29 | 2026-06-23 |
| Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC receive treatment with TROP2-targeted ADC and targeted molecular PET/CT imaging using ⁶⁸Ga-MY6349 injection - NSCLC, EGFR Activating Mutation | Phase 2 | Not yet recruiting | Zhou Chengzhi | 100 | 2026-07-01 | 2026-07-06 |
| A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC SYS6010 - NSCLC | Phase 1 | Not yet recruiting | Sichuan University | 21 | 2026-06-30 | 2026-07-09 |
| Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer Toripalimab (240mg day1, Q3W*3cycle), Diphenhydramine, Platinum-based chemotherapy - NSCLC | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 120 | 2026-06-30 | 2026-06-12 |
| An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer HS-10504； midazolam - NSCLC | Phase 1 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 24 | 2026-06-27 | 2026-07-06 |
| Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC RYZ211/212 - Metastatic Urothelial Carcinoma, Breast Cancer | Early Phase 1 | Recruiting | RayzeBio, Inc. | 40 | 2026-06-15 | 2026-10-13 |
Showing 20 of 554. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (149) · Lung Neoplasms (66) · Melanoma (32) · Colorectal Neoplasms (31) · Neoplasm Metastasis (22) · Squamous Cell Carcinoma of Head and Neck (22) · Breast Neoplasms (21) · Neoplasms (21) · Ovarian Neoplasms (21) · Carcinoma, Renal Cell (17) · Stomach Neoplasms (16) · Pancreatic Neoplasms (15) · Brain Neoplasms (14) · Head and Neck Neoplasms (14) · Triple Negative Breast Neoplasms (14)
Neoplasms by Site (249) · Neoplasms (237) · Respiratory Tract Diseases (190) · Lung Diseases (186) · Respiratory Tract Neoplasms (186) · Thoracic Neoplasms (186) · Bronchial Neoplasms (152) · Carcinoma, Bronchogenic (152) · Lung Neoplasms (118) · Neoplasms by Histologic Type (76) · Neoplasms, Glandular and Epithelial (61) · Skin Diseases (55) · Skin and Connective Tissue Diseases (55) · Digestive System Diseases (51) · Digestive System Neoplasms (51)
Pemetrexed (45) · Carboplatin (39) · pembrolizumab (37) · Cisplatin (27) · Paclitaxel (23) · Drug Therapy (21) · Docetaxel (20) · osimertinib (19) · Gefitinib (14) · Nivolumab (14) · Radiotherapy (14) · aflutinib (12) · durvalumab (12) · Erlotinib Hydrochloride (11) · Gemcitabine (11)
Tianjin Medical University Cancer Institute and Hospital (12) · Shanghai Chest Hospital (10) · Shanghai Pulmonary Hospital, Shanghai, China (9) · Allist Pharmaceuticals, Inc. (7) · AstraZeneca (7) · Memorial Sloan Kettering Cancer Center (7) · Pfizer (7) · Guangdong Association of Clinical Trials (6) · Sun Yat-sen University (6) · TYK Medicines, Inc (6) · Betta Pharmaceuticals Co., Ltd. (5) · Fudan University (5) · Henan Cancer Hospital (5) · Jiangsu Province Nanjing Brain Hospital (5) · Maastricht Radiation Oncology (5)
China (204) · United States (154) · France (42) · Italy (40) · Spain (39) · Australia (36) · South Korea (35) · Germany (34) · Netherlands (32) · Canada (26) · United Kingdom (25) · Taiwan (20) · Belgium (15) · Japan (14) · Poland (14)
Anne-Marie Dingemans, MD, PhD (2) · Athanasios Karambeazis, MD (2) · Baohui Han, MD (2) · Caicun Zhou (2) · Chunxia Su, Phd (2) · Daniel Morgensztern, M.D. (2) · Eric Ng, MD (2) · Giuseppe Giaccone, M.D. (2) · Jackie Walling, MBChB, PhD (2) · Lambros Vamvakas, MD (2)
PMID 20573926, PMID 25175099, PMID 31809241, PMID 34903471, PMID 37476372, PMID 41037823, PMID 15118073, PMID 15118125, PMID 15886314, PMID 16642476, PMID 19403881, PMID 19470276, PMID 20087963, PMID 21300929, PMID 21831418, PMID 22388712, PMID 22560555, PMID 23816960, PMID 23857398, PMID 23857959, PMID 24002608, PMID 24114964, PMID 24168104, PMID 24188056, PMID 24218513, PMID 24562641, PMID 24868440, PMID 25572091, PMID 25601652, PMID 25784657, PMID 25900186, PMID 25921002, PMID 26095785, PMID 26334749, PMID 26338178, PMID 26484629, PMID 26582738, PMID 26762738, PMID 26858122, PMID 26951040, PMID 27121209, PMID 27393505, PMID 27441744, PMID 27539328, PMID 27566586, PMID 28065465, PMID 28303530, PMID 28802255, PMID 28945850, PMID 28973074
2023 (8), 2018 (3), 2019 (3), 2014 (2), 2015 (2), 2016 (2), 2017 (2), 2005 (1), 2008 (1), 2025 (1), 5UG1CA189824-08 (1), P01CA217797 (1), P30CA086862 (1), U01CA140206 (1)